Bridging the Organoid Translational Gap: Integrating Standardization and Micropatterning for Drug Screening in Clinical and Pharmaceutical Medicine

The document discusses the challenges and potential solutions for translating organoid technology from laboratory settings to clinical and commercial applications. Despite their success in predicting drug efficacy, organoids face obstacles in clinical implementation. Key strategies to bridge this gap include environmental and phenotypic recapitulation, 3D patterning, matrix engineering, and multi-modality information acquisition. The integration of engineering methodologies and standardized organoid models in clinical and pharmaceutical applications is crucial for advancing translational organoid technologies, offering promising directions for future development.